This is an international observational study in patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism.
Study Type
OBSERVATIONAL
Enrollment
6,784
Patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator
Unnamed facility
Multiple Locations, Austria
Unnamed facility
Multiple Locations, Belgium
Unnamed facility
Multiple Locations, Canada
Adjudicated major bleeding events
Time frame: after 1 year or until 30 days after end of rivaroxaban therapy
Safety variables will be summarized using descriptive statistics based on adverse events collection
Time frame: after 1 year or until 30 days after end of rivaroxaban therapy
All cause mortality
Time frame: after 1 year or until 30 days after end of rivaroxaban therapy
Adjudicated symptomatic thromboembolic events
Time frame: after 1 year or until 30 days after end of rivaroxaban therapy
Persistence with rivaroxaban treatment: Reasons for any switch from or interruption of rivaroxaban treatment
Time frame: after 1 year or until 30 days after end of rivaroxaban therapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Multiple Locations, Czechia
Unnamed facility
Multiple Locations, Denmark
Unnamed facility
Multiple Locations, France
Unnamed facility
Multiple Locations, Germany
Unnamed facility
Multiple Locations, Hungary
Unnamed facility
Multiple Locations, Ireland
Unnamed facility
Multiple Locations, Israel
...and 11 more locations